# Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of RLS Symptoms

> **NCT00389831** · PHASE2 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 44 (actual)

## Conditions studied

- Restless Legs Syndrome

## Interventions

- **DRUG:** Rotigotine Nasal Spray
- **OTHER:** Placebo Nasal Spray

## Key facts

- **NCT ID:** NCT00389831
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2006-11
- **Final completion:** 2006-12
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2014-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00389831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00389831, "Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of RLS Symptoms". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00389831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*